|
|
Vol. 12.12 – 28 March, 2023
|
|
|
|
|
|
|
|
Investigators identified circulating tumor cell biomarkers and effective combinations of tumor-initiating stem-like cell-specific, repurposed FDA-approved drugs.
[Advanced Science]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers reported that terminally exhausted (TTEX) cells actively participated in tumor progression by modulating CSCs. TTEX cells strongly correlated with elevated CSC frequency in poorly immune-infiltrated advanced human breast and ovarian carcinomas.
[Cancer Research]
|
|
|
|
|
|
Monodisperse hollow-structured MnO2 was successively modified with hyaluronic acid to enhance targeting CSCs with high CD44 expression levels.
[ACS Applied Materials & Interfaces]
|
|
|
|
|
|
Investigators reported a novel derivative of lonidamine, namely HYL001, which selectively and potently inhibited CSCs by targeting mitochondria.
[Pharmacological Research]
|
|
|
|
|
|
Scientists presented DNA aptamers capable of specific binding to glial tumor cells in vitro, ex vivo, and in vivo for visualization diagnostics of central nervous system tumors.
[Molecular Therapy – Nucleic Acids]
|
|
|
|
|
|
Harmine was identified as a hit compound based on phenotypic screening of a 2D assay and patient-derived organoid model that was established from a patient with multiple drug resistance and breast metastases.
[Cancer Letters]
|
|
|
|
|
|
Researchers investigated the molecular and funcitonal makeup of ovarian CSCs (OCSCs) in clinically relevant model systems, and revealed that Matrix Gla Protein was markedly enriched in OCSCs.
[Cell Death & Disease]
|
|
|
|
|
|
The authors investigated the effects of histone methyltransferases 2, EHMT2 or G9a, on immunosuppressive tumor microenvironment and whether this effect was related to changes on cell stemness.
[CNS Neuroscience & Therapeutics]
|
|
|
|
|
|
The in vitro and in vivo study demonstrated that tumor necrosis factor-α-induced protein-8-like-2 (TIPE2) sensitized breast cancer cells to paclitaxel by suppressing drug-induced autophagy and CSC properties.
[Human Cell]
|
|
|
|
|
|
|
|
|
The authors summarize the biological hallmarks and markers of CSCs, and the nanotechnology-based therapies to eradicate them.
[Daru-Journal Of Pharmaceutical Sciences]
|
|
|
|
|
|
|
|
The FDA outlined plans to move away from single-arm studies and instead favor randomized controlled trials that can potentially serve as the basis for both accelerated and full approval.
[Fierce Biotech]
|
|
|
|
|
|
|
|
July 24 – 28, 2023
Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
University of Pennsylvania – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
Columbia University – New York City, New York, United States
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Umbilical & Placental Cell News